Evidence map›Paper›PMID 41438253›Full record

ArticleOpen access rheumatology : research and reviews2025

Association of miR-145-5p, miR-143-3p and miR-146a-5p with Simplified Disease Activity Index in Rheumatoid Arthritis.

Beatriz Teresita Martín Márquez, Fernanda Isadora Corona Meraz, Andrea Aguilar-Vázquez, Itzel Yoselin Arteaga Gallegos, Judith Alejandra Esparza Michel, Alvaro Jovanny Tovar-Cuevas, Milton Omar Guzmán-Ornelas, Roberto Carlos Rosales Gómez, Flavio Sandoval García, Oscar Pizano Martínez and 4 more

Abstract read
In one paragraph

Article in Open access rheumatology : research and reviews, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Beatriz Teresita Martín Márquez *Department of Molecular Biology and Genomics, Research Institute in Rheumatology and Musculoskeletal System (IIRSME), Health Sciences University Center (CUCS), University of Guadalajara, Guadalajara, Jalisco, Mexico.ORCID 0000-0002-6756-4316
Fernanda Isadora Corona Meraz *Department of Biomedical Sciences, Division of Health Sciences, University Center of Tonalá (Cutonalá), University of Guadalajara, Tonalá, Jalisco, Mexico.
Andrea Aguilar-VázquezSecretariat of Sciences, Humanities and Technologies (SECIHTI), Mexico City, Mexico.
Itzel Yoselin Arteaga GallegosDepartment of Rheumatology, Secretariat of Sciences, Humanities and Technologies (SECIHTI), Internal Medicine Division, New Civil Hospital Dr. Juan I. Menchaca, University of Guadalajara, Guadalajara, Jalisco, México.
Judith Alejandra Esparza MichelDepartment of Rheumatology, Secretariat of Sciences, Humanities and Technologies (SECIHTI), Internal Medicine Division, New Civil Hospital Dr. Juan I. Menchaca, University of Guadalajara, Guadalajara, Jalisco, México.
Alvaro Jovanny Tovar-CuevasDepartment of Biomedical Sciences, Division of Health Sciences, University Center of Tonalá (Cutonalá), University of Guadalajara, Tonalá, Jalisco, Mexico.ORCID 0000-0002-0394-6737
Milton Omar Guzmán-OrnelasDepartment of Biomedical Sciences, Division of Health Sciences, University Center of Tonalá (Cutonalá), University of Guadalajara, Tonalá, Jalisco, Mexico.ORCID 0000-0002-6077-7925
Roberto Carlos Rosales GómezDepartment of Biomedical Sciences, Division of Health Sciences, University Center of Tonalá (Cutonalá), University of Guadalajara, Tonalá, Jalisco, Mexico.
Flavio Sandoval GarcíaDepartment of Molecular Biology and Genomics, Research Institute in Rheumatology and Musculoskeletal System (IIRSME), Health Sciences University Center (CUCS), University of Guadalajara, Guadalajara, Jalisco, Mexico.
Oscar Pizano MartínezDepartment of Molecular Biology and Genomics, Research Institute in Rheumatology and Musculoskeletal System (IIRSME), Health Sciences University Center (CUCS), University of Guadalajara, Guadalajara, Jalisco, Mexico.
Edy David Rubio ArellanoDepartment of Physiology, Health Sciences University Center (CUCS), University of Guadalajara, Guadalajara, Jalisco, Mexico.ORCID 0000-0002-3337-7934
Gabriela Paola García-OrdoñezDepartment of Physiology, Health Sciences University Center (CUCS), University of Guadalajara, Guadalajara, Jalisco, Mexico.
Christian Juarez-GomezDepartment of Physiology, Health Sciences University Center (CUCS), University of Guadalajara, Guadalajara, Jalisco, Mexico.
Mónica Vázquez-Del MercadoDepartment of Molecular Biology and Genomics, Research Institute in Rheumatology and Musculoskeletal System (IIRSME), Health Sciences University Center (CUCS), University of Guadalajara, Guadalajara, Jalisco, Mexico.ORCID 0000-0002-3823-4676

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: MicroRNAs (miR) have emerged as key regulatory molecules in immune response and inflammation. This study investigated the association between the plasma expression levels of miR-146a-5p, miR-143-3p, miR-145-5p and rheumatoid arthritis (RA) clinical activity measured by standard tools such as the Simplified Disease Activity Index (SDAI). Patients and Methods: Forty-eight RA patients fulfilling the EULAR/ACR 2010 criteria and 39 clinical apparently healthy subjects (HS) were included. Patients were categorized based on disease clinical activity using standard scores. Expression levels of miR were determined by RT-qPCR to be analyzed in the context of disease clinical activity, serum inflammation markers and autoantibodies such as rheumatoid factor (RF) and anti-cyclic citrullinated peptide antibodies (anti-CCP). Bioinformatic analysis was performed to assess gene interactions and signaling pathways. Results: The expression of miR-146a-5p showed higher expression in patients with low or moderate clinical disease activity. In addition, miR-145-5p was negatively correlated with both RF and anti-CCP antibodies. Bioinformatic analysis revealed that the miRs could simultaneously regulate myosin VI ( Conclusion: Our findings suggest that the plasma levels of the analyzed miR are associated with key serological markers and low to moderate disease clinical activity in RA patients according to SDAI score. The bioinformatics data supports the potential for these miRs to regulate genes involved in RA pathology.

Indexed as

inflammationmiRRASDAI

Identifiers

PMID41438253
PMCPMC12719922

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.